Brind.
  1. Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).

Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.

4 reports, 2 independent Updated Sep 8
Gone quiet
Reports
4
Developments
4
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.

Who's involved

What this event is mainly about
AmgenNovartis

How it developed

Newest first. Tap a step to see who reported it.
  1. Market reaction to Novartis trial results impacts Amgen's investor standing.1 source
  2. Novartis study setbacks raise risk profile for Amgen; Novartis secures global rights from Ionis.1 source
  3. Mizuho lifted price objective on Amgen; filing with SEC reports institutional investment.1 source
  4. Amgen benefits from Novartis/Ionis Phase 3 research while facing tax dispute and analyst scrutiny.1 source

Keep exploring

Part of

Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).

Also in this story

All 7 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped